CTVA Corteva
Durable seed franchise inside a commoditizing chemicals shell; first check whether the quoted price is real.
The story
Corteva is a mature, global agricultural inputs company, roughly 60% seed (Pioneer germplasm and trait licensing, a durable franchise) and 40% crop protection (facing generic Chinese competition and pricing pressure). It is mid-way through a self-help margin story: royalty-neutral transition to its own Enlist/Vorceed traits, biologicals and cost cuts. A planned separation of seed and crop protection could expose the seed franchise's value, though the consolidated whole remains a slow-growth, cyclical business.
Growth of about 3.5% reflects flat 5-year revenue with seed pricing power offset by crop protection deflation. Margin rises from 10.9% to 14% (not the 16% or more management targets) as royalty savings and cost programs land but crop protection stays commoditized. Sales-to-capital is set at 0.9 rather than the reported 0.67 because the reported figure is depressed by merger goodwill and incremental reinvestment is lighter. Beta sits just below the 1.1 materials anchor because farm demand is defensive. Confidence is low because the inputs look inconsistent: a $13.24 price and 667M shares give an $8.8B market cap against $1.16B of net income (about 7.6x P/E), which does not match how CTVA has historically traded. This may be a split, spin-off or data error, so the price should be verified before acting on any margin of safety.
Value drivers
| Revenue growth (Y1) | 3.5% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 14.0% |
| Years to target margin | 5 |
| Sales-to-capital | 0.90 |
| Beta | 0.95 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.5% |
| Terminal WACC | 8.6% |
Valuation bridge
| PV of explicit FCFF | 6.76B |
| PV of terminal value | 14.39B |
| Equity value | 22.62B |
| ÷ shares → per share | $33.91 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 18.52B | 3.5% | 11.5% | 1.52B | 695.68M | 821.01M | 757.01M |
| 2 | 19.15B | 3.4% | 12.1% | 1.65B | 705.34M | 949.25M | 807.02M |
| 3 | 19.79B | 3.4% | 12.7% | 1.80B | 714.32M | 1.08B | 850.20M |
| 4 | 20.44B | 3.3% | 13.4% | 1.95B | 722.59M | 1.23B | 886.94M |
| 5 | 21.10B | 3.2% | 14.0% | 2.11B | 730.11M | 1.38B | 917.63M |
| 6 | 21.76B | 3.1% | 14.0% | 2.17B | 736.83M | 1.44B | 882.65M |
| 7 | 22.43B | 3.1% | 14.0% | 2.24B | 742.72M | 1.50B | 848.33M |
| 8 | 23.10B | 3.0% | 14.0% | 2.31B | 747.73M | 1.56B | 814.69M |
Key risks
- Generic crop-protection pricing pressure from Chinese producers compresses margins
- Execution and stranded costs from the seed/crop-protection separation
- Farm income downturn, weather and commodity price cycles reduce input demand
Catalysts
- Completion of the separation unlocking a seed-pure-play valuation
- Royalty cost savings from the shift to proprietary traits driving margin expansion toward 14-16%
⚠ Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.